期刊文献+

胱抑素C水平与冠心病的相关性研究 被引量:24

Correlation between cystatin C level and coronary heart disease
下载PDF
导出
摘要 目的了解胱抑素C水平与冠状动脉病变严重程度的关系。方法选择疑诊冠心病且行选择性冠状动脉造影的冠心病患者114例(冠心病组).根据临床病史和冠状动脉造影结果分为2组:急性冠状动脉综合征(acute coronarysyndromes,ACS)组73例,稳定性心绞痛(stable angina pectoris,SAP)组41例;另选择非冠心病(冠状动脉造影阴性)患者38例作为对照组。采用Gensini评分系统对冠状动脉病变程度进行评分。应用免疫比浊法测定血清胱抑素C水平。分析血清胱抑素C水平与冠状动脉病变严重程度及病变支数的相互关系。结果 ACS组和SAP组血清胱抑素C水平明显高于对照组[(2.2±3.5)mg/L vs(1.6±4.1)mg/L vs(0.7±2.9)mg/L,P<0.01].且ACS组血清胱抑素C水平明显高于SAP组(P<0.05)。Gcnsini积分≥30分患者血清胱抑素C水平明显高于Gensini积分<30分患者[(2.6±2.7)mg/L vs(1.8±5.2)mg/L,P<0.01]。3支病变患者血清胱抑紊C水平和Gensini积分较单支病变和双支病变患者明显增高[(2.8±1.8)mg/L vs(1.9±3.4)mg/L vs(2.1±4.1)mg/L;(49±16)分v5(17±9)分vs(28±1 8)分,P<0.05,P<0.01];双支病变患者Gensin积分较单支病变患者明显增高(P<0.01);而单支病变与双支病变患者血清胱抑素C水平差异无统计学意义(P>0.05)。血清胱抑素C水平与冠状动脉病变严重程度Gensini积分呈正相关(r=0.673,P<0.01)。结论胱抑素C水平与冠状动脉病变严重程度及病变支数显著相关,胱抑素C水平可以作为评价冠状动脉病变严重程度的一个指标。 Objective To study the correlation between cystatin C level and severity of coronary heart disease(CHD). Methods One hudred and fourteen patients with CHD were divided into acute coronary syndrome(ACS) group(n= 73) and stable angina pectoris(SAP) group(n= 41). Thirty-eight non-CHD patients with negative coronary angiogragraphy(CAG) served as a control group. Severity of CHD was scored using the Gensini scoring system. Correlation of serum cystatin C level and severity of CHD with lesions of coronary arteries was analyzed. Results The serum cystatin C level was significantly higher in ACS group and SAP group than in control group (2.2±3.5 mg/L vs 1.6±4. 1 mg/I. vs 0. 7±2. 9 mg/L,P〈0.01),in ACS group than in SAP group(P〈0. 05), in patients with their Gensini score ≥30 than in those with their Gensini score〈30(2.6±2.7 mg/L vs 1.8±5.2 mg/L,P〈0.01) ,and in patients with triple vessel disease than in those with single Vessel disease(P〈0. 01),but no significant difference was found be tween patients with triple vessel disease or single vessel disease(P〉0.05). The cystatin C level was positively correlated the Gensini score of CHD severity (r= 0. 673, P〈0.01). Conclusion Cystatin C level is significantly correlated with the severity of CHD and the number of compro raised coronary arteries,and can thus be used as a marker in assessing the severity of CHD.
出处 《中华老年心脑血管病杂志》 CAS 北大核心 2012年第3期264-267,共4页 Chinese Journal of Geriatric Heart,Brain and Vessel Diseases
关键词 半胱氨酸蛋白酶抑制剂 冠心病 冠状血管造影术 急性冠状动脉综合征 一氧化氮 cysteine proteinase inhibitors coronary disease coronary angiography acute coronary syndrome nitric oxide
  • 相关文献

参考文献10

  • 1李屏,熊晓昉.血尿酸和脂蛋白-a水平与冠状动脉病变程度的关系[J].贵阳医学院学报,2008,33(1):19-21. 被引量:4
  • 2Sean CH, Robert DS, Cheryl A. Conover genetic deletion of pregnancy'associated plasma proteiny A is associated with resistance to atherosclerotic lesion development in apolipoprotein E deficient mice challenged with a high fat diet. Circulation Research,2007,100 : 1696- 1702.
  • 3Ix J H, Mercado N, Shlipak MG, et al. Association of chronic kidney disease with clinical outcomes after coronary revascularization: The Arterial Revascularization Therapies Study (ARTS). Am H cart J,2005,149:512-519.
  • 4Reznichenko NE, Panphilova EIu, Evdokimova MA, et al. Cystatin C level is independently related to risk of unfavorable outcome after acute coronary syndrome in individuals with normal or moderately reduced enalfunction. Kardiologiia, 2011,51:4-10.
  • 5Funayama A, Watanabe T, Tamabuchi T, et al. Elevated cystatin C levels predict the incidence of vasospastic angina. Clin ical and Experimental Immunology, 2009,156 : :386-394.
  • 6Qi JH,Wang Y,Gao F,et al, Enhanced stabilization of ather osclerotic plaques apolipoprotein E knockout mice by combi-natorial Toll like receptor 1 and 2 gene silencing. Human Gene Therapy, 2009,20 : 739-750.
  • 7Huang F,Thompson JC,Wilson PG, et al. Angiotensin II increases vascular proteoglycan content preceding and contributing to atherosclerosis development. J Lipid Res, 2008, 49: 521-530.
  • 8Newby AC, George SJ, Ismail Y, et al. Vulnerable atherosclerotic plaque metalloproteinases and foam cell phenotypes. Thromb Haemost, 2009,101 : 1006-1011.
  • 9Rekabi V,Davoodi G. Correlation between lipoprotein(a) ser um concentration and severity of coronary artery stenosis in an Iranian population according to Gensini score. Clinical Biochemistry, 2008,41 : 117-120.
  • 10Brunetti ND, Pellegrino PL, Gorreale M, et al. Acute phase proteins and systolic dysfunction in subjects with acute myocardial infarction. J Thromb Thrombolysis, 2008,26 : 197 -203.

二级参考文献13

  • 1Department of Internal Medicine. Yone zawa City Hospital Lipoprotein (a) is a potential coronary risk factor [ J ]. JPN Circ J ,2000 ( 1 ) :51 - 56.
  • 2Freedman DS, Williamson DF , Gunter EW, et al. Relation of serum uric acid to mortality and isehemie heart disease. The NGANESI Epidemiologic follow up study [ J ]. Am J Epidemiol, 1995 (7) : 637 - 644.
  • 3Gensini GG. A more meaningful scoring system for determining the severity of coronary heart disease[J]. Am J Cardiol, 1983 (51) :606.
  • 4Moreno PR, Falk E, Palacios IF, et al. Macropnage infiltration in acute coronary syndromes : Implication for plaque rupture [ J ]. Circulation, 1994 (2) :775 - 778.
  • 5Rosengren A, Wilhelmsen L. Lipoprotein (a) and coronary heart disease: a prospective case control study in a general population sample of middle aged men [ J ]. BMJ , 1990(6763 ) : 1248 - 1251.
  • 6Budde T. Plasm Lp (a) levels correlate with number, scverty, and length, extendion of cornary lesions in male patients undergoing coronary atherosclerosis [ J ]. Arthioscler Thromb, 1994 ( 14 ) : 1730.
  • 7Suarna C, Dean RT, May J, et al. Human atherosclerotic plaque contains both oxidized lipids and ascorbate [ J ]. Arterioscler Thromb, 1995 (10) : 1616 - 1624.
  • 8Ginsberg MH, Kozin F, OM alley M , et al. Release of platelet constituents by mono sodium urate crystals [ J ]. J Clin Invest, 1997(60) :999 - 1007.
  • 9Johnson R J, Kang D, Feig DI. Is there a pathogenetie role for uric acid in hypertension and cardiovascular and renal disease [ J ]. Hypertension ,2003 (41) : 1183 - 1187.
  • 10Alderman MH, Aiyer KJ. Uric acid: Role in cardiovascular disease and effect of losartan [ J ]. Curt Med Res Opin, 2004 (3) :369 - 379.

共引文献3

同被引文献242

引证文献24

二级引证文献167

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部